Trial Profile
Management of moderate to severe plaque psoriasis with Kyntheum in daily practice
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 16 Oct 2023
Price :
$35
*
At a glance
- Drugs Brodalumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms LIBERO
- Sponsors LEO Pharma GmbH
- 13 Oct 2023 According to a LEO Pharma media release, pooled analysis data of DELTA 1 & DELTA 2 will be presented at the 32nd European Academy of Dermatology and Venereology (EADV) Congress from the 11th to the 14th of October in Berlin, Germany.
- 07 Sep 2020 Status changed from recruiting to active, no longer recruiting.
- 26 Aug 2019 Planned number of patients changed from 500 to 700.